35 completed, 3 unknown, 2 active not recruiting, 2 recruiting. 28 Phase 1, 6 Phase 2, 3 Not applicable, 3 Phase 3, 3 Phase 4.
Follow Charcoal: new trials by email Literature Review of Charcoal trials Research Report on Charcoal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Activated Charcoal on Serum Osmolality, Osmolal Gap, and Enzymatic Ethylene Glycol Assay Activated Charcoal - Osmolality Disturbance, Lab Interference | Active not recruiting | State University of New York - Upstate Medical University | 8 | 2025-11-15 | 2026-07-31 | |
| Activated Charcoal Use in Chronic Kidney Disease Patients Activated Charcoal, Phosphate Binders - End Stage Renal Disease (ESRD), CKD 5D, Hemodialysis | Phase 2 | Recruiting | Mansoura University | 40 | 2025-08-01 | 2025-08-08 |
| Activated CHARcoal in Poisoned Patient - Pilot Trial Activated Charcoal, No activated charcoal - Charcoal, Decontamination, Poisoning | Phase 4 | Recruiting | Laval University | 100 | 2025-07-16 | 2026-01-29 |
| The Effect of Probiotics vs Activated Charcoal in the Management of CKD Patients Suffering From Uremic Pruritus. Probiotic Blend Capsule, Activated Charcoal - Chronic Kidney Disease, Uremic Pruritus | Phase 2 | Unknown | Ain Shams University | 123 | 2024-09-01 | 2024-08-30 |
| Bioequivalence of IMP 08P1707F0 Relative to Pulmicort® (1.0 Mg/2 Ml Suspension) budesonide, Activated Charcoal - Healthy | Phase 1 | Completed | Unither Pharmaceuticals, France | 24 | 2024-08-13 | 2024-11-08 |
| Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis Frexalimab, Teriflunomide, Placebo infusion - Multiple Sclerosis | Phase 3 | Active not recruiting | Sanofi | 1655 | 2023-12-13 | 2026-07-20 |
| Does a Soft Drink Mixture Improve Tolerance of Activated Charcoal in the Adult Poisoned Patient Without Affecting Efficacy Activated Charcoal - Overdose | Phase 4 | Completed | State University of New York - Upstate Medical University | 5 | 2023-01-04 | 2024-05-30 |
| Evaluation of Protective Effect of Activated Charcoal and Probiotic Against Progression of Chronic Kidney Disease Activated Charcoal, Probiotic, No intervention - Uremic Toxin | Phase 2 / Phase 3 | Unknown | Waleed Khaild Rahman Kareem Al-kabi | 60 | 2022-09-25 | 2022-09-14 |
| Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal) - Chronic Obstructive Pulmonary Disease | Phase 1 | Completed | AstraZeneca | 108 | 2022-07-29 | 2025-08-28 |
| A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy Participants Mavacamten, Activated Charcoal with Sorbitol - Healthy Participants | Phase 1 | Completed | Bristol-Myers Squibb | 45 | 2022-04-15 | 2022-11-08 |
| Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product Indacaterol/glycopyrronium - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 24 | 2022-02-28 | 2022-07-13 |
| Charcoal in Lung Cancer Patients Undergoing TEMLA Activated charcoal - Lung Cancer | Phase 2 | Withdrawn | Masonic Cancer Center, University of Minnesota | 2022-01-26 | 2022-02-09 | |
| Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics. Rivaroxaban, Activated charcoal - Healthy | Phase 1 | Completed | Centre Hospitalier Universitaire de Saint Etienne | 12 | 2022-01-03 | 2022-12-05 |
| Effects of CharcoCaps® (Activated Charcoal) vs. Placebo on Intestinal Gas Production Charcocaps, Placebo - Intestinal Gas | Not applicable | Completed | University of Memphis | 20 | 2021-09-30 | 2022-08-22 |
| Absorption of Indacaterol and Glycopyrronium From Ultibro Breezhaler Indacaterol maleate and glycopyrronium bromide, Ultibro Breezhaler with oral charcoal - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 34 | 2021-05-07 | 2021-09-28 |
| Pharmacokinetic Study Comparing Tiotropium Easyhaler® and Spiriva® HandiHaler® Tiotropium Bromide Monohydrate, Tiotropium Easyhaler with oral activated charcoal - Healthy Volunteers | Phase 1 | Completed | Orion Corporation, Orion Pharma | 43 | 2021-04-26 | 2021-10-25 |
| Role of Activated Charcoal in Decreasing Blood Urea, Creatinine and Phosphorous Activated charcoal, Dry seeds - Chronic Kidney Disease stage3 | Phase 2 | Unknown | Assiut University | 90 | 2020-08-01 | 2020-05-14 |
| To Study the Effect of Cenerimod on the Electrical Activity of the Heart, in Men and Women. To Study the Effect of Cenerimod on the Use of Oral Contraceptives in Women. To Study the Effect That Charcoal Has on the Elimination of Cenerimod From the Body, in Women and Men. Combined oral contraceptives (COC), Moxifloxacin 400mg, Cenerimod 0.5 mg - Healthy Subjects | Phase 1 | Completed | Viatris Innovation GmbH | 97 | 2020-01-31 | 2025-09-22 |
| A Pilot Feasibility Study of Activated Charcoal in Healthy Volunteers Activated charcoal and Tap Water, Activated Charcoal and Apple Juice - Healthy Adult Volunteers | Early Phase 1 | Completed | Masonic Cancer Center, University of Minnesota | 12 | 2020-01-22 | 2023-10-26 |
| Study To Determine Bioavailability of Sotagliflozin in Healthy Male and Female Subjects Sotagliflozin (SAR439954), 14C-microtracer, Charcoal - Type 2 Diabetes Mellitus, Healthy Subjects | Phase 1 | Completed | Sanofi | 6 | 2019-01-14 | 2022-04-25 |
Showing 20 of 44. Sign in to see all of them.
Anthrax (12) · Asthma (10) · Pulmonary Disease, Chronic Obstructive (4) · Poisoning (3) · Multiple Sclerosis (2) · Chronic Kidney Disease-Mineral and Bone Disorder (1) · Depressive Disorder, Major (1) · Diabetes Mellitus, Type 2 (1) · Drug Overdose (1) · Hemorrhagic Disorders (1) · Hypersensitivity (1) · Kidney Failure, Chronic (1) · Lung Neoplasms (1) · Malaria (1) · Renal Insufficiency, Chronic (1)
Orion Corporation, Orion Pharma (11) · Sanofi (3) · Centre Hospitalier Universitaire de Saint Etienne (2) · Eli Lilly and Company (2) · GlaxoSmithKline (2) · Masonic Cancer Center, University of Minnesota (2) · State University of New York - Upstate Medical University (2) · Zambon SpA (2) · Ain Shams University (1) · Assiut University (1) · AstraZeneca (1) · Bristol-Myers Squibb (1) · DynPort Vaccine Company LLC, A GDIT Company (1) · Emory University (1) · Hoffmann-La Roche (1)
United States (12) · Finland (10) · France (6) · United Kingdom (6) · Germany (3) · Belgium (2) · Canada (2) · China (2) · Turkey (Türkiye) (2) · Argentina (1) · Australia (1) · Austria (1) · Brazil (1) · Bulgaria (1) · Chile (1)
Leena Mattila, MD, PhD (3) · Aliaa Mohamed (1) · Armin J Rashidi, MD, PhD (1) · Armin Rashidi, MD, PhD (1) · Carl Skinner, MD (1) · Iissa Kivisto (1)
PMID 21079762, PMID 22897408, PMID 27910037, PMID 30055824, PMID 31253162, PMID 38926266, PMID 39899371, PMID 40834827, PMID 41677208
2015 (2), 2019 (2), 2014 (1), 2017 (1), 2023 (1), UL1TR002494 (1)